ProCE Banner Activity

Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease

Slideset Download
Conference Coverage
Proof-of-concept phase I data for mitapivat, an oral, small molecule inhibitor of pyruvate kinase R, shows early evidence of efficacy and safety in patients with stable sickle cell disease.

Released: December 16, 2020

Expiration: December 15, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology